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Abstract
Background: Our Thyroid-Multidisciplinary Clinic is a large referral site for thyroid diseases. Thyroid biopsies are
mainly performed for thyroid cancer screening. Yet, Hashimoto thyroiditis (HT) is being too frequently diagnosed.
The prevalence of HT is reported as 0.3-1.2% or twice the prevalence of type 1 diabetes. However, the prevalence
of HT confirmed by cytology is still uncertain. To evaluate different aspects of thyroid physiopathology including
prevalence of Hashimoto’s, a database of clinical features, ultrasound images and cytology results of patients
referred for FNA of thyroid nodules was prospectively developed.
Methods: We retrospectively studied 811 consecutive patients for whom ultrasound guided thyroid FNA biopsies
were performed at our clinic over 2.5 year period (Mar/2006-Sep/2008).
Results: The analysis of our database revealed that from 761 patients, 102 (13.4%) had HT, from whom 56 (7.4%)
were euthyroid or had sub-clinical (non-hypothyroid) disease, and 46 (6%) were clinically hypothyroid.
Conclusions: This is the first study to show such a high prevalence of HT diagnosed by ultrasound-guided FNA.
More strikingly, the prevalence of euthyroid HT, appears to be >5% similar to that of type 2 diabetes. Based on our
results, there might be a need to follow up on cytological Hashimoto’s to monitor for thyroid failure, especially in
high risk states, like pregnancy. The potential risk for thyroid cancer in patients with biopsy-proven inflammation of
thyroid epithelium remains to be established prospectively. However, it may explain the increased risk for thyroid
cancer observed in patients with elevated but within normal TSH.
Background
Hashimoto thyroiditis is the most common cause of
hypothyroidism in the United States [1]. With a 5-10
time preference over men, the reported prevalence in
white women is in the 1-2% range [2].
Etiology and pathogenesis of Hashimoto thyroiditis are
still elusive. Moreover, little is known about progression
of euthyroid to hypothyroid Hashimoto’s. At least in chil-
dren, disease progression from euthyroid to hypothyroid
Hashimoto thyroiditis has been suggested [3]. Also, avail-
able evidence relating the progression of sub-clinical to
overt hypothyroidism in adults has been rated as good
[4]. Hence, it is conceivable that a euthyroid stage of
Hashimoto thyroiditis exists and that progression to a
full-blown disease stage is a matter of time.
Since there is growing evidence that unrecognized
hypothyroidism is deleterious, early diagnosis of Hashi-
moto thyroiditis would be advantageous in predicting
thyroid failure. Specifically, it is well known that mater-
nal thyroid status assessment and treatment improves
fetal outcomes and neuropsychological developmental of
the newborn [5].
The University of Wisconsin Thyroid Multidisciplinary
Clinic is a large referral site for thyroid diseases in the
Midwest. A continuously increasing number of thyroid
biopsies are being performed every year for cancer
screening. Yet, Hashimoto thyroiditis is being too fre-
quently diagnosed. The prevalence of Hashimoto thyroi-
ditis is reported to be approximately twice that of type 1
diabetes. However, the prevalence of Hashimoto thyroi-
ditis confirmed by cytology has never been documented
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nodules. To evaluate different aspects of thyroid physio-
pathology, a database of clinical features, ultrasound
images and cytology results of patients referred for fine
needle aspiration of thyroid nodules was prospectively
developed. In this paper we probed our database for the
frequency and characteristic of patients diagnosed with
Hashimoto thyroiditis while being referred for thyroid
cancer screening.
Methods
Thyroid Database
From March 2006 until September 2008, 811 patients
underwent ultrasound guided fine needle aspiration
(FNA) biopsy of thyroid nodules for screening of thyroid
cancer. After excluding 50 patients who were either no-
show or their specimens were non-diagnostic, we retro-
spectively studied 761 consecutive patients for which
ultrasound guided thyroid FNA biopsies were performed
at our clinic (Figure 1). All FNA samples were reviewed
by cytopathologists at our institution.
The Hashimoto thyroiditis cohort consisted of 102
(13.4%) patients (659 out of 761 did not have cytological
Hashimoto’s diagnosis) for which 46 (6%) were identi-
fied as having clinical disease (i.e. diagnosed hypothyroid
on thyroid hormone replacement and with cytological
Hashimoto’s diagnosis), 9 (1.2%) as having sub-clinical
hypothyroidism (as defined by normal thyroid hormones
with above normal [usually less than 10 ng/dl] TSH and
with cytological Hashimoto’s diagnosis) and 47 (6.2%) as
having euthyroid autoimmunity (as defined by normal
thyroid hormones with normal [0.45-4.12 ng/dl] TSH
but with cytological Hashimoto’s diagnosis). For all
patients, data were collected for: age, gender, nodule
size and number of nodules, levels of TSH/FT4, pre-
sence of TPO (thyroid peroxidase) autoantibodies,
family history of Hashimoto’s, goiter, and autoimmune
diseases. The collection of patient’s data and subsequent
analysis was approved by University of Wisconsin
Human Subjects Institutional Review Board.
Statistical Analysis
Data analysis was conducted using Excel X2 and Fisher’s
exact test and Student t-test were used when appropri-
ate. Statistical significance was defined as P < 0.05.
Results
Patients Characteristics
Patients were referred to the University of Wisconsin
Thyroid Multidisciplinary Clinic usually for evaluation
of an already diagnosed thyroid problem. Thyroid
nodules ≥ 1 cm were biopsied under ultrasound gui-
dance mainly to screen for thyroid cancer. On-site cyto-
pathology was available for every single case. Endocrine
surgery referral was also available as needed during the
same encounter. A database was started with the inau-
guration of the clinic and recruitment is ongoing. Of the
first 811 patients’ data analyzed, an unexpected large
number of patients with positive Hashimoto thyroiditis
cytology were identified. The analysis of our database
revealed that from 761 patients, 102 (13.4%) had cytol-
ogy proven Hashimoto thyroiditis. Patients’ characteris-
tics of this cohort are shown on table 1. Hashimoto
thyroiditis cohort consisted of 94 female and 8 male
30 TPO not recorded
13 positive TPO
3 negative TPO
46 clinically hypothyroid (6%)
6 TPO not recorded
1 positive TPO
2 negative TPO
9  sub-clinical (1.2%)
102 Hashimoto's (13.4%) 659 No Hashimoto's
761 patients
47  euthyroid (6.2%)
34 TPO not recorded
7 positive TPO
6 negative TPO
Figure 1 Patients’ allocation diagram.
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102 patients with cytology-proven Hashimoto thyroidi-
tis, 47 (6.2%) were euthyroid, 9 (1.2%) had sub-clinical
hypothyroidism, and 46 (6%) had clinical hypothyroid-
ism and were on thyroid hormone replacement (Table 1
and Figure 2). The number of nodules was 1.43 ± 0.54
average for the clinically hypothyroid subgroup, 1.77 ±
0.66 average for the sub-clinical subgroup (p < 0.05
when compared to clinically hypothyroid subgroup) and
1.58 ± 0.71 for the euthyroid subgroup. The size of the
nodules was 1.42 ± 0.42; and 1.55 ± 0.81; for the clinical
and sub-clinical subgroups respectively and 1.69 ± 0.74
(p < 0.05, also Table 1) for the euthyroid subgroup.
Although differences between nodules sizes of clinically
hypothyroid versus sub-clinical subgroups appear signifi-
cant, the result of this comparison is skewed by the low
number of patients in the sub-clinical subgroup as well
as the wider range. Larger size of euthyroid subgroup
nodules was however statistically significant when com-
pared to clinically hypothyroid subgroup nodules both
subgroups with similar number of nodules. Another sig-
nificance difference was also observed in the comparison
of TSH values between euthyroid and clinically
hypothyroid subgroups as expected. The clinically
hypothyroid subgroup had an average TSH of 8 ± 2.61
ng/dl while the euthyroid subgroup had a lower TSH of
2.18 ± 1.14 ng/dl. The sub-clinical subgroup had average
TSH value of 6.73 ± 1.26 ng/dl. All nodules were
reported as benign. Of note, although patients with clin-
ical hypothyroidism were all taking thyroid hormone,
none in the sub-clinical or the euthyroid subgroups
Table 1 Patients Characteristics - Hashimoto Thyroiditis Patients*
Clinically hypothyroid Sub-clinically hypothyroid 1
st P-value** Euthyroid 2
nd P-value**
FNA patients 46 9 47
Age (years) 47 ± 12 50 ± 17 0.53 46 ± 15 0.72
Gender
Male 2 (4%) 2 (22%) 0.15 4 (9%) 0.68
Female 44 (96%) 7 (78%) 0.79 43 (92%) 1
Nodule
# of nodules 1.43 ± 0.54 1.77 ± 0.66 <0.05 1.58 ± 0.71 0.26
Size 1.42 ± 0.42 1.55 ± 0.81 0.48 1.69 ± 0.74 <0.05
TSH(0.45-4.12 ng/dl) 8 ± 2.61 6.73 ± 1.26 0.16 2.18 ± 1.14 <0.05
FT4 1 ± 0.36 0.96 ± 0.11 0.74 0.92 ± 0.11 0.15
Not Recorded 24 (52%) 5 (56%) 27 (57%)
Recorded 22 (48%) 4 (44%) 20 (43%)
TPO antibodies
Not Recorded 30 6 34
Positive 13 1 0.62 7 0.56
Negative 3 2 0.27 6 0.45
FHx of Hashimoto’s/goiter/autoimmunity 18 (39%) 4 (44%) 1 10 (21%) 0.19
* Values reported as mean ± SD.
** Fisher exact test and Student t-test. 1
st P-value is between Clinically and Sub-clinically hypothyroid. 2
nd P-value is between Clinically hypothyroid and
Euthyroid. Statistically significant values are shown in italics.
Cytological diagnosis (this study)
Biochemical diagnosis (NHANESIII) 
NON-HASIMOTO’S
Euthyroid 6.2 %
Sub-clinical 4.3 %
Clinically
Hypothyroid
6 %
Clinically
Hypothyroid
0.3 %
13.4 % Hashimoto’s total
4.6 % Hashimoto’s total
NON-HASIMOTO’S
Sub-clinical 1.2 %
Figure 2 Prevalence comparison. Chart comparison is provided
between this study and NHANES III (9). The total population of
NHANES III study is used as a reference for the comparison of
clinical and subclinical disease in both studies.
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the clinically hypothyroid subgroup was found to be 1 ±
0.36; 0.96 ± 0.11 in the sub-clinical and 0.92 ± 0.11 in
the euthyroid subgroup. FT4 however was not recorded
in 52% of the clinically hypothyroid subgroup and in 56/
57% of the sub-clinical/euthyroid subgroups respectively.
Not recorded also, was the presence or absence of TPO
autoantibodies in 30 of 46 patients with clinical
hypothyroidism, 6 of 9 patients with sub-clinical and 34
of 47 with euthyroid Hashimoto’s. However out of the
recorded TPO autoantibodies, 13 of 16 (81.3%) were
positive in the clinically hypothyroid subgroup while 8
of 16 (50%) were positive in the sub-clinical/euthyroid
subgroups (also in Table 1). There were no significant
differences among euthyroid, sub-clinical and clinically
hypothyroid Hashimoto thyroiditis subgroups in terms
of age, gender, family history of Hashimoto’s, goiter,
and/or autoimmune diseases (also in Table 1).
Hashimoto thyroiditis more common than expected
Although the prevalence of Hashimoto thyroiditis diag-
nosed by ultrasound guided FNA cytology has not been
established, the prevalence found in our cohort was
unexpectedly high in comparison with that reported for
Hashimoto’s hypothyroidism and subclinical disease
combined (Figure 2). The reasons for these differences
in prevalence estimates are not obvious. Hence we con-
sidered potential factors that might have biased the
results. Among them, the clinical indications for the
biopsies and the cytological criteria for Hashimoto thyr-
oiditis diagnosis were reviewed for all cases. Clinical
indications for biopsies of nodules were based on the
American Thyroid Association guidelines for size cri-
t e r i a( s e en o d u l es i z e si nT a b l e1 )w h i c hw e r ed e t e r -
mined by ultrasound before and confirmed during the
biopsy (Figure 3A as example). Standard cytological
characteristics for diagnosis were also followed by our
cytologists as described by Kini [6]. The cytological diag-
nosis of Hashimoto’s thyroiditis relied on the presence
of both an inflammatory infiltrate accompanied by thyr-
oid follicular cells. Mixed population of lymphocytes,
sometimes represented in the form of crushed lympho-
cytes and lymphoglandular bodies (cytoplasmic debris)
together with the presence of Hurthle cells were
described in all cytology reports (Figure 3B as example).
All of these characteristics were considered in the diag-
nosis of each and every patient in our cohort. Lastly,
our referral population is broad but representative of an
area considered iodine sufficient.
Discussion
This is the first study to show such a high prevalence of
Hashimoto thyroiditis diagnosed by ultrasound-guided
FNA cytology on a somewhat large cohort of patients.
Based on our study, the prevalence of cytology-proven
Hashimoto thyroiditis appears to be >10% in patients
with thyroid nodules. Given that the prevalence of thyr-
oid nodules on ultrasonography or autopsy data is as
high as 50% [7], such a high prevalence of Hashimoto
thyroiditis diagnosed by cytology is noteworthy. More
strikingly, the prevalence of euthyroid, non-previously
diagnosed, cytology-proven Hashimoto thyroiditis
(euthyroid autoimmunity), appears to be >5% in our
study (Figure 1 and 2). This condition has not been pre-
viously defined. For comparison, its prevalence is similar
to that of type 2 diabetes which is considered to be a
health care crisis.
Weetman [2] reported clinical Hashimoto thyroiditis
prevalence rate at 1 in 182 or 0.55% in the US. In the
UK, Tunbridge et al [8] reported an overall Hashimoto
thyroiditis prevalence of 0.8%. However, based on our
study, the cytology of Hashimoto thyroiditis seems to be
much more prevalent, at 13.4%. This difference may be
partially explained by the fact that for diagnosing clinical
Hashimoto thyroiditis, abnormally elevated TSH, low
thyroid hormones [2,8] and the confirmatory presence
of thyroid autoantibodies are usually accounted for. We
hypothesized then, that cytological diagnosis of Hashi-
moto’s may precede clinical diagnosis. Interestingly
however, in most organ specific autoimmune diseases,
humoral immunity heralds tissue infiltrative damage.
Hence, we expected the diagnosis of Hashimoto’sb y
cytology to be less but not more common than the anti-
body diagnosis especially on early stages of the disease
(Figure 2).
In an attempt at differentiating better the apparent
stages of Hashimoto thyroiditis, we divided our cytol-
ogy-proven Hashimoto’s cohort into three subgroups:
clinically hypothyroid, sub-clinical and euthyroid. For
these distinctions, we used the clinical definition of
hypothyroid Hashimoto thyroiditis as that occurring in
patients usually with TSH greater than 10 ng/dl at diag-
nosis, with low free thyroid hormones and on thyroid
hormone replacement. Based on NHANES III study [9]
normative data for TSH distribution (reference popula-
tion of 13,344, 95% of TSH between 0.45-4.12 ng/dl),
abnormally high TSH (but usually less than 10 ng/dl)
with normal thyroid hormones was used to define sub-
clinical hypothyroidism. Patients with those characteris-
tics were assigned to the sub-clinical subgroup in our
study. A third subgroup classified as euthyroid included
patients with normal thyroid hormones and normal
TSH.
Aside from the unexpected observation of the high
prevalence of Hashimoto thyroiditis by cytology, espe-
cially in euthyroid patients, the lack of cytological corre-
lation with TPO autoantibody positivity is noteworthy.
As mentioned before, the hallmark in the diagnosis of
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bodies [10]. Yet, only about half of the patients tested
for anti-TPO in the euthyroid subgroup were positive.
On the other hand and although non-statistically signifi-
cant because of the small number reported, the clinically
hypothyroid subgroup had most (13 out of 16 tested)
patients positive for anti-TPO. Similarly, Poropatich et
al., [11] found that anti-TPO and/or antithyroglobulin
antibody titers were present in only 50% of the patients
with euthyroid, cytology-proven Hashimoto thyroiditis, a
finding never reproduced by these or other authors in
the literature.
Given the wide range of normal values for TSH (1 fold)
and the variability on the presence of TPO autoantibodies,
it is conceivable that early Hashimoto’s autoimmune pro-
cess might be clinically missed. These issues, together with
the awareness that sub-clinical and clinical hypothyroid-
ism associates with cardiovascular and neuropsychiatric
Lymphoglandular
bodies
Hurthle Cells
Lymphocytic infiltrate
Crushed
lymphocytes
A
B
Figure 3 A. Ultrasound image of euthyroid Hashimoto thyroiditis. A representative ultrasound is shown of an asymptomatic, euthyroid
patient’s thyroid nodule cytologically diagnosed Hashimoto thyroiditis. Note the minimal color flow Doppler identified within the nodule.
B. Cytopathology. Cytological characteristics of a thyroid nodule with typical diagnostic features of Hashimoto’s thyroiditis (i.e. lymphocytic
infiltrate, Hurthle cells, lymphoglandular bodies and crushed lymphocytes).
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thyroiditis on cytology, especially in euthyroid patients
clinically significant [12-14].
An important aspect of our findings is the fact that
most of the patients in our cohort are pre-menopausal
females. Past and more recent studies found that the
risk of poor obstetrical outcome is increased with rela-
tive thyroxine deficiency [15-18]. Benhadi et al. recently
showed that the risk of miscarriage, fetal and neonatal
death is increased with higher TSH levels. Moreover,
the risk of fetal loss occurred even when maternal free
thyroxine levels were normal [16]. Based on our results
of high prevalence of cytology-proven Hashimoto thyroi-
ditis and especially high prevalence of euthyroid disease
in pre-menopausal women, there might be need of at
least follow up of thyroid function on cytologically-pro-
ven Hashimoto’s in pre-conception through delivery
stages.
Positive Hashimoto’s cytology clearly represents a state
in which inflammation of thyroid epithelium may lead
to tissue remodeling. Hence the possibility of acquiring
mutations while cells are dividing might be greater.
Some studies have suggested that inflammation of thyr-
ocytes could be linked to thyroid cancer [19-21]. For
example, Larson et al. showed that phosphatidylinositol
3-kinase phosphorilates Akt, which in turn suppresses
pro-apoptotic signals and promotes tumorigenesis, was
increased in both Hashimoto thyroiditis and well differ-
entiated thyroid cancer [19]. Furthermore, Borrello et
al., showed that RET/PTC oncogene, when exogenously
expressed in normal thyrocytes, induces expression of a
large set of genes involved in inflammation and tumor
invasion (cytokines, matrix-degrading enzymes and
adhesion molecules) [20]. There seem to be however,
controversial opinions regarding the association of
Hashimoto thyroiditis and thyroid cancer. Some studies
find Hashimoto thyroiditis as associated with thyroid
cancer [22,23] as examples, while others do not report
an association [24,25] as examples. Since higher TSH
level in patients with thyroid nodules has been found to
be associated with risk of differentiated thyroid cancer
[26,27], we hypothesized that active remodeling of thyr-
oid epithelium in cytological Hashimoto’s may explain
in part the increased risk for differentiated thyroid can-
cer observed in patients with elevated but within normal
TSH [26,27].
Conclusions
We report here that the pathogenesis of Hashimoto
thyroiditis is present in an unexpectedly large number
of individuals. Moreover, we found that many of these
individuals carry a non-clinically manifested process.
Biopsy proven Hashimoto thyroiditis in asymptomatic,
clinically disease-free patients is a condition still
undefined. There are no guidelines as to how to follow
these patients. What is theirr i s ko fp r o g r e s s i n gt of u l l -
blown Hashimoto’s? How would pregnancy affect their
thyroid function? Are they at further risk of developing
thyroid cancer since their TSH usually runs in the nor-
mal but higher quartile? Recognition of this entity
emerges as necessary at least in patients at risk for
hypothyroid complications (i.e. pregnancy). If the cytol-
ogy of Hashimoto thyroiditis represents a chronic active
inflammatory state, TSH elevations within normal limits
may represent a manifestation of a common underlying
process.
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